Three-dimensional structure of a Nanobody® (modeled on the VHH with pdb-code 1U0Q, Cambillau et al). The target molecule is recognized by the surface formed by three hypervariable regions located at the top of the molecule (in green, cyan and blue). Hallmarks, amino acid residues that further differentiate a camelid VHH from a human VH, can be located at different positions within the framework regions, and here are coloured red, pink and magenta.

Home INVESTOR RELATIONS Shareholder structure

Shareholder structure

Shareholder structure & information on capital, voting securities and voting rights

History of capital

Ablynx NV publishes the following information in accordance with Article 15 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"):

Total amount of the capital of the Company :

EUR 81,486,264.59

Total number of voting securities:

43,601,797

Total number of voting rights (denominator):

43,601,797

Ablynx NV has an aggregate of 3,568,076 outstanding warrants, 2,506,512 warrants of which entitle their holders to an aggregate of 1,253,256 shares (two warrants giving right to subscribe for one share) and 1,061,564 warrants of which entitle their holders to an aggregate of 1,061,564 shares (one warrant giving right to subscribe for one share). The aggregate number of voting rights that can be obtained upon exercise of the outstanding warrants amounts to 2,314,820.

Ablynx NV has not issued any other rights to subscribe for voting securities that have not yet been issued or any shares without voting rights.

The voting securities of Ablynx NV are not divided into categories.

The Articles of Association of Ablynx NV provide for an additional notification threshold of 3%.

This information is valid as of 21 April 2010. In accordance with the Transparency Law, changes to the information set out above will be published ultimately by the end of the calendar month during which the relevant change has occurred.

Shareholder structure

In accordance with Article 14 of the Belgian Transparency Law, Ablynx hereby publishes its shareholder structure.

Holdings as per 1 September 2008

Ablynx received the following notifications of holdings as per 1 September 2008. The denominator as per 1 September 2008 amounted to 36,438,959.

NOTIFYING PERSON(S)

number

of voting rights

percentage

of voting rights

Gimv NV, Adviesbeheer Gimv Life Sciences NV, Adviesbeheer Gimv Life Sciences 2004 NV and Biotech Fonds Vlaanderen NV

6,924,764

19.00%

Sofinnova Partners SAS

5,927,830

16.27%

Abingworth Management Limited and Abingworth LLP

4,102,952

11.26%

Alta California Partners IV, LP

3,135,583

8.61%

Gilde Europe Food & Agribusiness Fund B.V.

2,941,772

8.07%

C.H. Boehringer Sohn AG & Co. KG and Boehringer Ingelheim International GmbH

2,142,857

5.88%

Multifund B.V., Nederlandia Investments B.V. and Stichting Avivia

1,900,000

5.21%

KBC Groep NV and KBC Private Equity NV

1,589,286

4.36%

VIB VZW

1,375,000

3.77%

Holdings as per 18 March 2010

Ablynx received the following notifications of holdings as per 18 March 2010. The denominator as per 18 March 2010 amounted to 43,590,173.

NOTIFYING PERSON(S)

number

of voting rights

percentage

of voting rights

Gimv NV, Adviesbeheer Gimv Life Sciences NV, Adviesbeheer Gimv Life Sciences 2004 NV and Biotech Fonds Vlaanderen NV

7,991,431

18,33%

C.H. Boehringer Sohn AG & Co. KG and Boehringer Ingelheim International GmbH

2,142,857

4,92%

Multifund B.V., Nederlandia Investments B.V. and Stichting Avivia

1,900,000

4,36%

KBC Groep NV and KBC Private Equity NV

1,264,822

2,90%

Holdings as per 21 April 2010

Ablynx received the following notification of holding as per 21 April 2010. The current denominator as per 21 April 2010 amounted (and still amounts) to 43,601,797.

NOTIFYING PERSON(S)

number

of voting rights

percentage

of voting rights

KBC Groep NV and KBC Private Equity NV

1,411,556

3,24%

Shareholder structure as per 21 April 2010 – for information purposes only

Based on (i) the number of voting rights set out in the notifications received by Ablynx as per 1 September 2008 (following the entry into force of the Belgian Transparency Law), and (ii) the new number of voting rights set out in the notifications received by Ablynx as per 18 March 2010, and taking into consideration the current denominator (43,601,797), Ablynx hereby states, for information purposes only, that the shareholder structure would be the following:

NOTIFYING PERSON(S)

 

Number of voting rights notified on1/09/2008

Number of voting rights notified on 18/03/2010 and21/04/2010 respectively

Hypothetical percentage of voting rights based on current denominator and most recent notifications

Gimv NV, Adviesbeheer Gimv Life Sciences NV, Adviesbeheer Gimv Life Sciences 2004 NV and Biotech Fonds Vlaanderen NV

6,924,764

7,991,431

18.33%

Sofinnova Partners SAS

5,927,830

-

13.60%

Abingworth Management Limited and Abingworth LLP

4,102,952

-

9.41%

Alta California Partners IV, LP

3,135,583

-

7.19%

Gilde Europe Food & Agribusiness Fund B.V.

2,941,772

-

6.75%

C.H. Boehringer Sohn AG & Co. KG and Boehringer Ingelheim International GmbH

2,142,857

2,142,857

4.92%

Multifund B.V., Nederlandia Investments B.V. and Stichting Avivia

1,900,000

1,900,000

4.36%

VIB VZW

1,375,000

-

3.15%

KBC Groep NV and KBC Private Equity NV

1,589,286

1,411,556

3.24%

Transparency notifications

Article 15 of the Articles of Association of the Company has set the threshold requiring a transparency declaration at 3%, 5% and each subsequent multiple of 5%.

Latest News


27/07/2010

ABLYNX ANNOUNCES CHANGE IN MANAGEMENT

23/07/2010

ABLYNX ANNOUNCES WARRANT EXERCISE

12/07/2010

NOVARTIS OBTAINS LICENSES TO DEVELOP AND COMMERCIALISE TWO NOVEL NANOBODIES®


Email alerts

If you would like to receive updates on the company news, please
click here